September 29, 2010 — In a prospective study published in the European Journal of Nuclear Medicine and Molecular Imaging, researchers at Boca Raton Regional Hospital, Boca Raton, Fla., showed that positron emission mammography (PEM) and breast magnetic resonance imaging (MRI) had a comparably high ability to detect cancerous lesions.

The prospective study enrolled 182 women with recent biopsy-proven primary breast cancer. It also found that PEM was not impacted by menopausal status, breast density or hormone replacement therapy, making PEM a valuable alternative.

PEM scanners are high-resolution breast positron emission tomography (PET) systems that show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians to make the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.” PEM is different from X-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease in a patient already diagnosed with a primary breast cancer.

“We were very pleased to find that PEM and MRI had comparable ability to detect cancerous lesions regardless of type or severity of the tumor,” said Kathy Schilling, M.D., lead author on the study. “In addition, the data showed that PEM is a fantastic alternative for women with dense breasts or where timing of an MRI due to menstrual cycle is challenging. The next step is to understand how PEM and MRI compare when differentiating between benign and malignant suspicious lesions.”

Results from a separate NIH-sponsored clinical study (NIH Grant 5R44CA103102), recently presented at the 2010 Society of Nuclear Medicine Annual Meeting, comparing PEM and breast MRI help answer Dr. Schilling’s question. The multi-site study of hundreds of women with newly diagnosed breast cancer shows that PEM demonstrated a 6 percent improvement in specificity, ability to differentiate between malignant and benign lesions, suggesting that PEM may reduce unnecessary biopsies. These results are particularly significant for women who cannot tolerate an MRI exam and require an alternate imaging tool. The study is slated for publication in the December issue of the journal Radiology.

For more information: naviscan.com


Related Content

News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

April 27 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Computed Tomography (CT)

April 23, 2026 — Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Time April 30, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Radiology Business

April 28, 2026 — The American Society of Radiologic Technologists will award Life Member status to three longstanding ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Radiology Business

April 24, 2026 — The 2026 vacancy rate for radiation therapists decreased to 11.4% and the vacancy rate for medical ...

Time April 24, 2026
arrow
News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Artificial Intelligence

April 20, 2026 — DeepTek, provider of the Augmento platform and deepc, the company behind deepcOS, have introduced a ...

Time April 23, 2026
arrow
News | Radiology Imaging

April 20, 2026 — Bracco Imaging has announced a strategic alliance with NYU Langone Health to advance innovation in ...

Time April 23, 2026
arrow
Subscribe Now